KRAS and colorectal carcinoma: In an attempt to improve the understanding of immune activity in molecular subgroups of CRC, we analysed the distribution of different immune cell subsets in relation to tumour MSI/MSS status, CMS subtype, as well as BRAF and KRAS mutation status, and identified several significant relations (Figure 2).